CN101683461B - Application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage - Google Patents
Application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage Download PDFInfo
- Publication number
- CN101683461B CN101683461B CN 200810079431 CN200810079431A CN101683461B CN 101683461 B CN101683461 B CN 101683461B CN 200810079431 CN200810079431 CN 200810079431 CN 200810079431 A CN200810079431 A CN 200810079431A CN 101683461 B CN101683461 B CN 101683461B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage of patients with chronic heart failure. The traditional Chinese medicine composition according to the invention is mainly composed of Radix Astragali, Radix et Rhizoma Ginseng, Radix et Rhizoma Salviae Miltiorrhizae etc., eleven traditional Chinese medicine, experimental results show that, the traditional Chinese medicine composition can reduce content of malonaldehyde (MDA) effectively, improve activity of superoxide dismutase (SOD), and inhibit oxidation damage of patients with chronic heart failure.
Description
Technical field
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, relate to the application of a kind of Chinese medicine composition in the medicine of preparation inhibition Patients with Chronic Heart Failure oxidative damage.
Background technology
The normal human can produce a small amount of oxygen-derived free radicals, and they play an important role in the system of defense of body and detoxification system, and body also exists a series of free radicals to eliminate system simultaneously, can in time remove oxygen-derived free radicals.Increase or antioxidant radical material activity decreased when oxygen-derived free radicals generates, body can produce oxygen-derived free radicals and pile up, and then makes lipid peroxidation, causes peroxide injury.Superoxide dismutase (SOD) can be removed superoxide anion, and Cell protection is avoided damage, and its vigor can reflect the ability of body removing oxygen-derived free radicals; Malonaldehyde (MDA) is a kind of lipid peroxide that oxygen-derived free radicals causes lipid peroxidation, and its content can reflect the degree of cell injury.Oxygen-derived free radicals can produce myocardial cell injury, induces apoptosis of cardiac muscle, causes myocardial remodelling and Heart function fails, and the cell injury that hypokinetic myocardial cell is induced oxygen-derived free radicals is more responsive, thereby produces a series of vicious cycle.(Ma Qilin thanks bravely, Zhang Saidan, and Peng is genuine, Ceng Xiaolin. and the variation of oxygen free radicals in congestive heart failure and vasorel are on its impact. Hunan Medical University's journal, 2002,27 (6) .)
Under the physiological conditions, the generation of oxygen-derived free radicals and remove and keep dynamic equilibrium in the body, during heart failure because myocardial ischemia-anoxemia, oxygen-derived free radicals is produced to be increased, remove simultaneously active decline of system of defense of oxygen-derived free radicals, thereby oxygen-derived free radicals is further increased, can damage again cardiac muscle and cause or increase the weight of heart failure.
It is generally acknowledged that oxidative damage can affect cardiac function by the following aspects: act on myocardial cell membrane generation lipid peroxidation injury, affect cardiac function and finally cause cardiomyocyte cell death; Make myocardial mitochondria swelling, disintegrate, dyssynthesis, cause myocardial contraction to descend; Destroy lysosome membrane, discharge the other phospholipase of phospholipase and activated membrane, destroy membrane phospholipid, it is excessive until aqtocytolysis that the myocardial contraction composition occurs when serious; Also make high molecular weight protein sarcostyle contracture, fracture, destruction microsome, nucleic acid and membrane receptor, affect metabolism and the contractile function of myocardial cell; Etc..
Therefore, heart failure patient can be by reducing MDA content, and it is active to improve SOD, comes the inhibited oxidation damage.
The present invention is the improvement invention of carrying out on the basis of Chinese patent ZL02146573.8, quotes in full the content of this patent document record at this.Chinese patent ZL02146573.8 does not put down in writing the application of this Chinese medicine composition in suppressing Patients with Chronic Heart Failure oxidative damage medicine.
Summary of the invention
The object of the invention provides the application of a kind of Chinese medicine composition in preparation inhibition Patients with Chronic Heart Failure oxidative damage medicine;
More preferably, this Chinese medicine composition improves the activity of superoxide dismutase (SOD) by effectively reducing the content of Patients with Chronic Heart Failure malonaldehyde (MDA), suppresses the oxidative damage of Patients with Chronic Heart Failure.
Drug main of the present invention will be comprised of the 11 flavor Chinese medicines such as the Radix Astragali, Radix Ginseng, Radix Salviae Miltiorrhizae, has the effect of temperature compensation heart kidney yang gas and activating blood and promoting diuresis.Effective ingredient Radix Ginseng total saponins among the we, danshensu etc. all can effectively remove oxygen-derived free radicals, suppress the lipid peroxidation that many factors causes and be conducive to the integrity of cellular morphology and function.
Described Chinese medicine composition is made by the crude drug of following weight portion:
Radix Astragali 150-450 part, Radix Aconiti Lateralis Preparata 40-120 part, Radix Ginseng or Radix Codonopsis 75-225 part, Radix Salviae Miltiorrhizae 75-225 part, Semen Lepidii (Semen Descurainiae) 50-150 part, Cortex Periplocae or CORTEX ACANTHOPANACIS 60-180 part, Rhizoma Alismatis 75-225 part, Rhizoma Polygonati Odorati 25-75 part, Ramulus Cinnamomi 30-90 part, Flos Carthami 30-90 part, Pericarpium Citri Reticulatae 25-75 part;
Preferably, described Chinese medicine composition is made by the crude drug of following weight portion:
450 parts of the Radixs Astragali, 112.5 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 225 parts of Radix Codonopsis, 225 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 180 parts of CORTEX ACANTHOPANACIS, 225 parts of Rhizoma Alismatis, 75 parts of Rhizoma Polygonati Odorati, 90 parts of Ramulus Cinnamomi, 90 parts on Flos Carthami, 75 parts of Pericarpium Citri Reticulataes;
Preferably, described Chinese medicine composition is made by the crude drug of following weight portion:
250 parts of the Radixs Astragali, 112.5 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 200 parts of Radix Codonopsis, 120 parts of Radix Salviae Miltiorrhizaes, 135 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 150 parts of CORTEX ACANTHOPANACIS, 200 parts of Rhizoma Alismatis, 60 parts of Rhizoma Polygonati Odorati, 75 parts of Ramulus Cinnamomi, 75 parts on Flos Carthami, 60 parts of Pericarpium Citri Reticulataes.
The active component of Chinese medicine composition of the present invention can be made by the extraction process of routine [such as model Bi Ting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition)], more preferably, the active component of described Chinese medicine composition is comprised of the effective ingredient that the following step makes:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng or Radix Codonopsis, Cortex Periplocae or CORTEX ACANTHOPANACIS are doubly measured 70% ethanol extraction with 7-9, filter, concentrated extracting solution to relative density when 60 ℃ of heat are surveyed is the clear paste of 1.25-1.30;
(2) volatile oil of extraction Ramulus Cinnamomi, Pericarpium Citri Reticulatae;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 6-10 times of water gaging decoction 2 times, and each 2 hours, merge extractive liquid, filtered; The aqueous solution that Ramulus Cinnamomi, Pericarpium Citri Reticulatae are carried behind the oil filters, and collects aqueous solution filtrate, adds 6-10 times of water gaging again and decocts residue 1 hour, filters, and merges aqueous solution; The various aqueous solutions of above-mentioned gained are merged, and being concentrated into relative density is the 1.25-1.30 clear paste, adds ethanol in the stirring, to determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated into that relative density is the 1.25-1.30 clear paste when 60 ℃ of heat are surveyed.
The present invention also provides the preparation method of this Chinese medicinal composition capsules agent:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng or Radix Codonopsis, Cortex Periplocae or CORTEX ACANTHOPANACIS are proportionally measured take by weighing and added 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid,, filter, decompression filtrate recycling ethanol is concentrated into relative density and is the clear paste of 1.25-1.30 (60 ℃ of heat are surveyed), and is for subsequent use;
(2) Ramulus Cinnamomi, Pericarpium Citri Reticulatae distillating extracting oil proportionally, the aqueous solution of carrying behind the oil filters, and for subsequent use, residue adds 8 times of water gagings again and decocted 1 hour, filters, and merges decocting liquid, and is for subsequent use;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 9 times of amount decoctions of water 2 times, each 2 hours, merge extractive liquid,, filter, merge with Ramulus Cinnamomi, Pericarpium Citri Reticulatae decocting liquid in the step (2), being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, add ethanol in the stirring, left standstill below 70%, 4 ℃ 24 hours to determining alcohol, filter, decompression filtrate recycling ethanol, being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, mixes 65-70 ℃ of oven dry with the alcohol extraction clear paste of step (1);
(4) step (3) gained dried cream powder is broken into 100 order powder, adds 70% appropriate amount of ethanol and granulate, spray into Ramulus Cinnamomi, Pericarpium Citri Reticulatae volatile oil, mixing, encapsulated, and get final product.
In the Chinese medicine composition of the present invention, as the latin name of the crude drug of active component and processing method thereof from " Chinese medicine voluminous dictionary " (in July, 1977, front page, Shanghai science tech publishing house) and " Chinese pharmacopoeia (version in 2005, Chemical Industry Press).
Chinese medicine composition of the present invention can also be routinely preparation process, for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record, make the acceptable any conventional dosage form of pharmaceutics, such as capsule, tablet, granule, powder, oral liquid or pill etc.
In the application of the present invention, described Chinese medicinal composition preparation dosage form is capsule, tablet, granule, powder, oral liquid or pill, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the acceptable adjuvant of pharmacy, such as: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
The consumption of Chinese medicine composition of the present invention, by active component crude drug gross weight, be the 4-20 gram/day, but take every day once, be preferably minute 2-4 time and take, also be preferably the 6-12 gram/day, take minute 2-4 time, more preferably 7.59 restrain/day, divide and take for 3 times.
The activity that suppresses the Patients with Chronic Heart Failure oxidative damage for illustrating Chinese medicine composition of the present invention is with having carried out following test by the prepared medicine of embodiment method (hereinafter referred to as medicine of the present invention).
1, animal
Healthy Wistar rat, the cleaning level, male and female half and half, body weight 200～240g is purchased from the Animals In Hebei Province experimental center, credit number: SCXK (Ji) 2003-1-003.Raising is in pharmacological room of Hebei Yiling Pharmaceutical Research Institute, illumination 12 hours/day, 20～23 ℃ of temperature, relative humidity 40～60%.Rat is raised in cages, 5/cage.Rat feed is full-valence pellet feed, is provided by Hebei province's Experimental Animal Center.Adaptability was raised three days.
2, medicine
Medicine of the present invention provides (lot number: 20000601), test and be made into desired concn with distilled water by Shijiazhuang Yiling Pharmaceutical Co., Ltd.
3, experimental technique
3.1 grouping and modeling
Rat is divided into 3 groups at random: sham operated rats, model group, medicine 4.8g crude drug of the present invention/kg dosage group.Every group 10.To desired concn, the administration volume is 10ml/kg to medicine with distilled water diluting, and route of administration is oral.
Adopt the attenuates pressure-overload left legal system to make chronic heart failure (heart failure) rat model.Rat pentobarbital sodium intraperitoneal injection of anesthesia, the xiphoid-process median incision of lower abdomen, divide the layer open abdominal cavity, at the free ventral aorta of the above passivity of renal artery branch, with No. 7 parallel the placing on the ventral aorta of syringe needle,, then slowly syringe is withdrawn from ventral aorta and together ligation of syringe with 4 trumpeter's art silk threads, close abdomen, layering is sewed up.Making rat aorta diameter constriction is 0.7mm.Sham operated rats is opened the silk thread of will performing the operation behind the abdomen and is passed ventral aorta, and except the constriction ventral aorta not, other operations are identical with model group.Postoperative 3 week beginning oral administration, once a day.4 weeks of successive administration.
3.2 hemodynamic index:
Through the carotid artery intubate, lead physiograph record left ventricular systolic pressure, left ventricular end diastolic pressure, left ventricular pressure rising and decline maximal rate, heart rate with four.
3.3MDA, SOD detects:
Get each treated animal and do contents of mda and the active detection of SOD, undertaken by the test kit description.
3.4HE dyeing:
Put to death rat, get left compartment muscle, 10% formalin is fixed, and conventional H E dyeing is observed under the light microscopic.
3.5 electron microscopic observation:
Get left compartment muscle, be cut into 1mm on ice
3Cardiac muscular tissue's piece places 4 ℃ of 5% glutaraldehydes to fix 24 hours, send the Electron Microscopy Room embedding, makes ultrathin section, observes under the transmission electron microscope.
3.6 the statistical analysis experimental data adopts SPSS11.5 version software kit to carry out statistical procedures.Experimental data represents with mean ± standard deviation.Use one factor analysis of variance, the P＜0.05 conduct inspection level that there was a significant difference.
4, result
4.1 the impact on the chronic heart failure rats hemodynamic index:
Compare with sham operated rats, chronic heart failure group left ventricular end diastolic is pressed, heart rate significantly raises (P＜0.01), systolic pressure, diastolic pressure, mean pressure, left ventricular systolic pressure, left ventricular pressure maximum contraction rate, the maximum diastolic rate of left ventricular pressure significantly reduce (P＜0.01), heart tonifying power group diastolic pressure, left ventricular systolic pressure, left ventricular end diastolic are pressed, heart rate significantly is lower than chronic heart failure group (P＜0.01), and left ventricular pressure maximum contraction rate, the maximum diastolic rate of left ventricular pressure are significantly higher than chronic heart failure group (P＜0.01).See Table 1.
Table 1 is on the impact of chronic heart failure rats hemodynamic index (x ± s)
Compare with sham operated rats
*##P＜0.01 is compared with model group in P＜0.05
4.2 the impact on chronic heart failure rats SOD, MDA:
Model group and sham operated rats ratio, MDA content obviously rise (P＜0.01), and SOD is active obviously to descend (P＜0.01), heart tonifying power group and model group ratio, and MDA content obviously descends (P＜0.01), active obviously rise (P＜0.01) of SOD.See Table 2.
Table 2 is on the impact of chronic heart failure rats SOD, MDA (X ± S)
Compare with sham operated rats
*P＜0.05; Compare ##P＜0.01 with model group
4.3HE dyeing:
The visible sham operated rats cardiac muscle fiber of om observation is arranged in order, and band is clear.The obvious cloudy swelling of model group rat myocardial cell, the dissolving of part muscle fiber, fracture, band disappears, and endochylema cavity sample becomes, myocardium interstitial edema, visible inflammatory cell infiltration.Medicine group of the present invention can obviously be improved above-mentioned pathological change.
4.4 electron microscopic observation:
Electron microscopic observation visible sham operated rats myocardium myo fibril and myofilament are arranged in order, and the light and shade band is clear, and mitochondrion is arranged in order, and morphosis is normal; The obvious broadening in model group rat heart muscle sarcostyle gap, arrangement disorder, visible focal myofilament dissolving, mitochondria number increases, arrangement disorder, obvious tumefaction, the fracture of part ridge or disappearance, visible sarcoplasmic reticulum is obviously expanded.Medicine group of the present invention can obviously be improved above-mentioned pathological change.
5, conclusion
This experiment light microscopic and Electronic Speculum can be observed: behind the heart failure, and the obvious cloudy swelling of rat myocardial cell, the dissolving of part muscle fiber, fracture, band disappears, endochylema cavity sample becomes, myocardium interstitial edema, inflammatory cell infiltration, mitochondria number increases, arrangement disorder, obvious tumefaction, the fracture of part ridge or disappearance, visible sarcoplasmic reticulum is obviously expanded, can obviously improve above-mentioned pathological change after the Drug therapy of the present invention, improve cardiac function.After experimental result shows heart failure, the MDA content increase, SOD is active to descend, and gives can obviously reduce MDA content after the Drug therapy of the present invention, and it is active to improve SOD.
In sum, medicine of the present invention can obviously reduce MDA content, and it is active to improve SOD, suppresses the Patients with Chronic Heart Failure oxidative damage.
The specific embodiment
Embodiment 1: the preparation of medicine capsule of the present invention
Prescription:
Radix Astragali 450g Radix Aconiti Lateralis Preparata 112.5g Radix Ginseng 225g Radix Salviae Miltiorrhizae 225g Semen Lepidii (Semen Descurainiae) 150g
Cortex Periplocae 180g Rhizoma Alismatis 225g Flos Carthami 90g Rhizoma Polygonati Odorati 75g Pericarpium Citri Reticulatae 75g Ramulus Cinnamomi 90g
Preparation method:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng, Cortex Periplocae are added 8 times of amount 70% alcohol reflux 2 times according to above-mentioned prescription, 3 hours for the first time, 2 hours for the second time, merge extractive liquid,, filter, decompression filtrate recycling ethanol is concentrated into relative density and is the clear paste of 1.25-1.30 (60 ℃ of heat are surveyed), and is for subsequent use;
(2) Ramulus Cinnamomi, Pericarpium Citri Reticulatae be according to the prescription distillating extracting oil, and the aqueous solution of carrying behind the oil filters, and for subsequent use, residue adds 8 times of water gagings again and decocted 1 hour, filters, and merges decocting liquid, and is for subsequent use;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 9 times of amount decoctions of water 2 times, each 2 hours, merge extractive liquid,, filter, merge with Ramulus Cinnamomi, Pericarpium Citri Reticulatae decocting liquid in the step (2), being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, add ethanol in the stirring, left standstill below 70%, 4 ℃ 24 hours to determining alcohol, filter, decompression filtrate recycling ethanol, being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, mixes 65-70 ℃ of oven dry with the alcohol extraction clear paste of step (1);
(4) dried cream mixed powder is broken into 100 order powder, adds 70% appropriate amount of ethanol and granulates, and sprays into Ramulus Cinnamomi, Pericarpium Citri Reticulatae volatile oil, and mixing is encapsulated, makes 1000, and get final product.
Embodiment 2: the preparation of medicinal tablet of the present invention
Prescription:
Radix Astragali 150g Radix Aconiti Lateralis Preparata 40g Radix Ginseng 225g Radix Salviae Miltiorrhizae 225g Semen Lepidii (Semen Descurainiae) 50g
Cortex Periplocae 180g Rhizoma Alismatis 75g Rhizoma Polygonati Odorati 75g Ramulus Cinnamomi 30g Flos Carthami 90g Pericarpium Citri Reticulatae 25g
Preparation method:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng, Cortex Periplocae are added 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time according to above-mentioned prescription, merge extractive liquid,, filter, filtrate subtracts with the alcohol extraction clear paste of step (1) mixes 65-70 ℃ of oven dry;
(2) Ramulus Cinnamomi, Pericarpium Citri Reticulatae be according to the prescription distillating extracting oil, and the aqueous solution of carrying behind the oil filters, and for subsequent use, residue adds 8 times of water gagings again and decocted 1 hour, filters, and merges decocting liquid, and is for subsequent use;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 9 times of amount decoctions of water 2 times, each 2 hours, merge extractive liquid,, filter, merge with Ramulus Cinnamomi, Pericarpium Citri Reticulatae decocting liquid in the step (2), being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, add ethanol in the stirring, left standstill below 70%, 4 ℃ 24 hours to determining alcohol, filter, decompression filtrate recycling ethanol, being concentrated into relative density is 1.25-1.30 (60 ℃ of heat are surveyed) clear paste, mixes 65-70 ℃ of oven dry with the alcohol extraction clear paste of step (1);
(4) formulation method is made tablet routinely.
Embodiment 3: the preparation of medicine oral liquid of the present invention
Prescription:
Radix Astragali 250g Radix Aconiti Lateralis Preparata 112.5g Radix Codonopsis 200g Radix Salviae Miltiorrhizae 120g Semen Lepidii (Semen Descurainiae) 135g
CORTEX ACANTHOPANACIS 150g Rhizoma Alismatis 200g Rhizoma Polygonati Odorati 60g Ramulus Cinnamomi 75g Flos Carthami 75g Pericarpium Citri Reticulatae 60g
Preparation method: formulation method is made oral liquid routinely.
Claims (9)
1. a Chinese medicine composition suppresses application in the chronic heart failure oxidative damage medicine in preparation, it is characterized in that described Chinese medicine composition made by the crude drug of following weight portion:
Radix Astragali 150-450 part, Radix Aconiti Lateralis Preparata 40-120 part, Radix Ginseng or Radix Codonopsis 75-225 part, Radix Salviae Miltiorrhizae 75-225 part, Semen Lepidii (Semen Descurainiae) 50-150 part, Cortex Periplocae or CORTEX ACANTHOPANACIS 60-180 part, Rhizoma Alismatis 75-225 part, Rhizoma Polygonati Odorati 25-75 part, Ramulus Cinnamomi 30-90 part, Flos Carthami 30-90 part, Pericarpium Citri Reticulatae 25-75 part.
2. application as claimed in claim 1 is characterized in that described Chinese medicine composition made by the crude drug of following weight portion:
450 parts of the Radixs Astragali, 112.5 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 225 parts of Radix Codonopsis, 225 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 180 parts of CORTEX ACANTHOPANACIS, 225 parts of Rhizoma Alismatis, 75 parts of Rhizoma Polygonati Odorati, 90 parts of Ramulus Cinnamomi, 90 parts on Flos Carthami, 75 parts of Pericarpium Citri Reticulataes.
3. application as claimed in claim 1 is characterized in that described Chinese medicine composition made by the crude drug of following weight portion:
150 parts of the Radixs Astragali, 40 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 225 parts of Radix Codonopsis, 225 parts of Radix Salviae Miltiorrhizaes, 50 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 180 parts of CORTEX ACANTHOPANACIS, 75 parts of Rhizoma Alismatis, 75 parts of Rhizoma Polygonati Odorati, 30 parts of Ramulus Cinnamomi, 90 parts on Flos Carthami, 25 parts of Pericarpium Citri Reticulataes.
4. application as claimed in claim 1 is characterized in that described Chinese medicine composition made by the crude drug of following weight portion:
250 parts of the Radixs Astragali, 112.5 parts of Radix Aconiti Lateralis Preparatas, Radix Ginseng or 200 parts of Radix Codonopsis, 120 parts of Radix Salviae Miltiorrhizaes, 135 parts of Semen Lepidii (Semen Descurainiae)s, Cortex Periplocae or 150 parts of CORTEX ACANTHOPANACIS, 200 parts of Rhizoma Alismatis, 60 parts of Rhizoma Polygonati Odorati, 75 parts of Ramulus Cinnamomi, 75 parts on Flos Carthami, 60 parts of Pericarpium Citri Reticulataes.
5. such as each described application of claim 1-4, it is characterized in that the active component of described Chinese medicine composition is made by the following step:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng or Radix Codonopsis, Cortex Periplocae or CORTEX ACANTHOPANACIS are doubly measured 70% ethanol extraction with 7-9, filter, concentrated extracting solution to relative density when 60 ℃ of heat are surveyed is the clear paste of 1.25-1.30;
(2) volatile oil of extraction Ramulus Cinnamomi, Pericarpium Citri Reticulatae;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 6-10 times of water gaging decoction 2 times, and each 2 hours, merge extractive liquid, filtered; The aqueous solution that Ramulus Cinnamomi, Pericarpium Citri Reticulatae are carried behind the oil filters, and collects aqueous solution filtrate, adds 6-10 times of water gaging again and decocts residue 1 hour, filters, and merges aqueous solution; The various aqueous solutions of above-mentioned gained are merged, and being concentrated into relative density is the 1.25-1.30 clear paste, adds ethanol in the stirring, to determining alcohol 70%, leaves standstill, and filters, and filtrate is concentrated into that relative density is the clear paste of 1.25-1.30 when 60 ℃ of heat are surveyed.
6. such as each described application among the claim 1-4, it is characterized in that described Chinese medicine composition is capsule, tablet, granule, powder, oral liquid or pill as the pharmaceutical preparation of active component.
7. application according to claim 6 is characterized in that, described capsule is to be made by following steps:
(1) Radix Astragali, Semen Lepidii (Semen Descurainiae), Rhizoma Alismatis, Radix Ginseng or Radix Codonopsis, Cortex Periplocae or CORTEX ACANTHOPANACIS are proportionally measured take by weighing and added 8 times of amount 70% alcohol reflux 2 times, 3 hours for the first time, 2 hours for the second time, merge extractive liquid,, filter, decompression filtrate recycling ethanol, relative density is the clear paste of 1.25-1.30 when being concentrated into 60 ℃ of heat surveys, and is for subsequent use;
(2) Ramulus Cinnamomi, Pericarpium Citri Reticulatae distillating extracting oil proportionally, the aqueous solution of carrying behind the oil filters, and for subsequent use, residue adds 8 times of water gagings again and decocted 1 hour, filters, and merges decocting liquid, and is for subsequent use;
(3) Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Polygonati Odorati, Flos Carthami add 9 times of amount decoctions of water 2 times, each 2 hours, merge extractive liquid,, filter, merge with Ramulus Cinnamomi, Pericarpium Citri Reticulatae decocting liquid in the step (2), relative density is the clear paste of 1.25-1.30 when being concentrated into 60 ℃ of heat surveys, add ethanol in the stirring, left standstill below 70%, 4 ℃ 24 hours to determining alcohol, filter, decompression filtrate recycling ethanol, relative density is the clear paste of 1.25-1.30 when being concentrated into 60 ℃ of heat surveys, mixes 65-70 ℃ of oven dry with the alcohol extraction clear paste of step (1);
(4) step (3) gained dried cream powder is broken into 100 order powder, adds 70% appropriate amount of ethanol and granulate, spray into Ramulus Cinnamomi, Pericarpium Citri Reticulatae volatile oil, mixing, encapsulated, and get final product.
8. such as each described application among the claim 1-4, it is characterized in that the application of this Chinese medicine composition in preparation reduction Patients with Chronic Heart Failure mda content medicine.
9. such as each described application among the claim 1-4, it is characterized in that the application of this Chinese medicine composition in preparation raising Patients with Chronic Heart Failure superoxide dismutase activity medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810079431 CN101683461B (en) | 2008-09-23 | 2008-09-23 | Application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810079431 CN101683461B (en) | 2008-09-23 | 2008-09-23 | Application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101683461A CN101683461A (en) | 2010-03-31 |
| CN101683461B true CN101683461B (en) | 2013-02-27 |
Family
ID=42046990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810079431 Active CN101683461B (en) | 2008-09-23 | 2008-09-23 | Application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101683461B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933339B (en) * | 2013-01-23 | 2019-04-23 | 河北以岭医药研究院有限公司 | A kind of application of Chinese medicine composition in the drug of preparation treatment depression |
| CN105801654B (en) * | 2014-12-29 | 2019-09-20 | 河北以岭医药研究院有限公司 | A kind of compound and its separation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (en) * | 2001-01-14 | 2001-08-01 | 刘红 | Medicine for treating congestive heart failure |
| CN1403149A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating chronic heart failure and its prepn |
-
2008
- 2008-09-23 CN CN 200810079431 patent/CN101683461B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (en) * | 2001-01-14 | 2001-08-01 | 刘红 | Medicine for treating congestive heart failure |
| CN1403149A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating chronic heart failure and its prepn |
Non-Patent Citations (2)
| Title |
|---|
| 李敏等.活血益气方药对心肌梗死后心力衰竭大鼠心肌细胞凋亡的影响.《中西医结合心脑血管病杂志》.2005,(第01期), * |
| 杨洪波等.慢性心功能不全与脂质过氧化关系的临床研究.《华南国防医学杂志》.2004,(第01期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101683461A (en) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN1931261B (en) | Blood pressure and blood lipid lowering capsule and its preparation process | |
| CN101849957B (en) | Application of Dendrobium officinale polysaccharide in preparation of medicine for preventing and treating hypertension and apoplexy | |
| CN101607006B (en) | Application of Chinese medicinal composition in preparing medicament for treating hypertension | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN104000944B (en) | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang | |
| CN102579560A (en) | Preparation method of Chinese angelica and astragalus mongholicus mixture aqueous extract, as well as application in intervening in pulmonary fibrosis | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN101683461B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for inhibiting oxidation damage | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN101590180A (en) | The application of a kind of Chinese medicine composition in preparation inhibition apoptosis of cardiac muscle medicine | |
| CN101897855A (en) | Medicament for treating uterine myoma | |
| CN102038821B (en) | Method for preparing medicinal composition for treating dysmenorrhea | |
| CN101653488B (en) | Application of Chinese medicinal composition in preparation of medicament for resisting myocardial stunning | |
| CN101099775B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN102861231B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating ventricular remodeling after myocardial infarction | |
| CN103083429A (en) | Blood fat-reducing traditional Chinese medicine formula | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN100509000C (en) | Dispersion tablet of red sage root for coronary artery and preparation method thereof | |
| CN1843454A (en) | Medicinal formulation for treating climacteric syndrome and its preparation method | |
| CN101590182A (en) | The application of a kind of Chinese medicine composition in the medicine of preparation reduction malignant cytokine level | |
| CN101658568B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary heart disease | |
| CN102895514B (en) | Application of Chinese medicine composition in preparing medicines for treating pulmonary heart disease | |
| CN101269162A (en) | Combination for auxiliary treatment of diabetes | |
| CN1298357C (en) | Bone-recovering tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |